Dose-intensive versus dose-control chemotherapy for high-grade osteosarcoma:ameta-analysis

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 9, 2014, Pages 1383-1390

  Wang, W ^a   Wang, Z C ^a   Shen, H ^a   Xie, J J ^a   Lu, H ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chemotherapy; Dose control chemotherapy; Dose intensive chemotherapy; Meta analysis; Osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; HUMAN; LIMB SALVAGE; META ANALYSIS; OSTEOSARCOMA; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; TREATMENT OUTCOME; TREATMENT RESPONSE; BONE NEOPLASMS; CANCER GRADING; CHI SQUARE DISTRIBUTION; DRUG ADMINISTRATION; MORTALITY; NECROSIS; PATHOLOGY; RISK; RISK FACTOR; TIME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; LIMB SALVAGE; NECROSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; OSTEOSARCOMA; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902195182     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. LACK W, DONIGAN JA, MORCUENDE J, BUCKWALTER J, EL-KHOURY GY. Conical utility of CT-guided biopsies in orthopaedic oncology. Iowa Orthop J 2010; 30: 76-79.
2. CHANG P. Progress in the treatment of osteosarcoma. Med Clin North Am 1977; 61: 1027-1030.
3. KANSARA M, THOMAS DM Molecular pathogenesis of osteosarcoma. DNA And Cell Biol 2007; 26: 1-18. (Pubitemid 46219587)
4. DAHLIN DC, COVENTRY MB Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am 1967; 49: 101-110.
5. ENNEKING WF. An abbreviated history of orthopaedic oncology in North America. Clin Orthop Relat Res 2000; 374: 115-124. (Pubitemid 30263479)
6. HUDSON M, JAFFE MR, JAFFE N, AYALA A, RAYMOND AK, CARRASCO H, WALLACE S, MURRAY J, ROBERTSON R. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 1990; 8: 1988-1997.
7. MEYERS PA, HELLER G, HEALEY J, HUVOS A, LANE J, MARCOVE R, APPLEWHITE A, VLAMIS V, ROSEN G. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10: 5-15.
8. BACCI G, AVELLA M, CAPANNA R, BORIANI S, DALLARI D, GALLETTI S, GIUNTI A, MADON E, MANCINI A, MERCURI M. Neoadjuvant chemotherapy in the treatment of osteosarcoma of the extremities: preliminary results in 131 cases treated preoperatively with methotrexate and cisdiamminoplatinum. Ital J Orthop Traumatol 1988; 14: 23.
9. BACCI G, PICCI P, FERRARI S, CASADEI R, BRACH DEL PREVER A, TIENGHI A, MANCINI A. Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies. J Chemother 1993; 5: 237-246. (Pubitemid 23309982)
10. BIELACK SS, BERON G, WINKLER K. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Cancer 1997; 80: 514-521.
11. BACCI G, FERRARI S, PICCI P, ZOLEZZI C, GHERLINZONI F, IANTORNO D, CAZZOLA A. Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs. J Chemother 1996; 8: 472-478. (Pubitemid 27022552)
12. BACCI G, GHERLINZONI F, PICCI P, VAN HORN JR, JAFFE N, GUERRA A, RUGGIERI P, BIAGINI R, CAPANNA R, TONI A, MARIO M, DANTE D, MARIO C. Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: A randomized study. Eur J Cancer Clin Oncol 1986; 22: 1337-1345. (Pubitemid 17183460)
13. BACCI G, FORNI C, FERRARI S, LONGHI A, BERTONI F, MERCURI M, DONATI D, CAPANNA R, BERNINI G, BRICCOLI A, SETOLA E, VERSARI M. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol 2003; 25: 845-853. (Pubitemid 37413833)
14. MEYERS PA, GORLICK R, HELLER G, CASPER E, LANE J, HUVOS AG, HEALEY JH. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998; 16: 2452-2458. (Pubitemid 28309040)
15. LEWIS IJ, NOOIJ MA, WHELAN J, SYDES MR, GRIMER R, HOGENDOORN PC, MEMON MA, WEEDEN S, USCINSKA BM, VAN GLABBEKE M, KIRKPATRICK A, HAUBEN EI, CRAFT AW, TAMINIAU AH; MRC BO06 AND EORTC 80931 COLLABORATORS; EUROPEAN OSTEOSARCOMA INTERGROUP. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-128.
16. SOUHAMI RL, CRAFT AW, VAN DER EIJKEN JW, NOOIJ M, SPOONER D, BRAMWELL VH, WIERZBICKI R, MALCOLM AJ, KIRKPATRICK A, USCINSKA BM, VAN GLABBEKE M, MACHIN D. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup. Lancet 1997; 350: 911-917. (Pubitemid 27420527)
17. WITTING JC, BICKELS J, PRIEBAT D, JELINEK J, KELLAR-GRANEY K, SHMOOKLER B, MALAWER MM Osteosarcoma: A multidisciplinary approach to diagnosis and treatment. Am Fam Physician 2002; 65: 1123-1133.
18. th study. Acta Oncol 1998; 37: 41-48. (Pubitemid 28179799)
19. FUCHS N, BIELACK S, EPLER D, BIELING P, DELLING G, KÖRHOLZ D, GRAF N, HEISE U, JÜRGENS H, KOTZ R, SALZER-KUNTSCHIK M, WEINEL P, WERNER M, WINKLER K. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998; 9: 893-899. (Pubitemid 28440449)
20. LINK MP, GOORIN AM, MISER AW, GREEN AA, PRATT CB, BELASCO JB, PRITCHARD J, MALPAS JS, BAKER AR, KIRKPATRICK JA. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 1600-1606. (Pubitemid 16118216)
21. ECKARDT J, EILBER F, DOREY F, MIRRA J. The UCLA experience in limb salvage surgery for malignant tumors. Orthopedics 1985; 8: 612-621. (Pubitemid 15026928)
22. DAMRON TA, PRITCHARD DJ Current combined treatment of high-grade osteosarcomas. Oncology-Huntington 1995; 9: 327-342.
23. MEYERS PA, GORLICK R. Osteosarcoma. Pediatr Clin North Am 1997; 44: 973-989. (Pubitemid 27368674)
24. WEEDEN S, GRIMER R, CANNON S, TAMINIAU A, USCINSKA B. The effect of local recurrence on survival in resected osteosarcoma. EurJ Cancer 2001; 37: 39-46. (Pubitemid 32119358)
25. PICCI P, SANGIORGI L, ROUGRAFF B, NEFF J, CASADEI R, CAMPANACCI M. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994; 12: 2699-2705. (Pubitemid 24379659)
26. PROVISOR AJ, ETTINGER LJ, NACHMAN JB, KRAILO MD, MAKLEY JT, YUNIS EJ, HUVOS AG, BETCHER DL, BAUM ES, KISKER CT, MISER JS. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 1997; 15: 76-84. (Pubitemid 27020560)